Exicure, Inc. (NASDAQ:XCUR) Sees Large Drop in Short Interest

Exicure, Inc. (NASDAQ:XCUR) was the target of a significant decrease in short interest in August. As of August 14th, there was short interest totaling 60,402 shares, a decrease of 43.8% from the July 30th total of 107,470 shares. Based on an average trading volume of 43,727 shares, the short-interest ratio is currently 1.4 days. Currently, 2.0% of the company’s stock are short sold.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded Exicure from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

Exicure Price Performance

NASDAQ XCUR traded up $0.06 on Monday, hitting $1.34. 4,878 shares of the stock were exchanged, compared to its average volume of 170,150. The business’s fifty day moving average is $1.70 and its 200 day moving average is $2.93. Exicure has a 52 week low of $1.05 and a 52 week high of $9.48. The company has a market capitalization of $8.81 million, a PE ratio of -1.02 and a beta of 3.65.

Exicure (NASDAQ:XCUR) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($18.60) by $18.42.

Exicure Company Profile

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.